Physician profile
Heidi Chun
NPI 1518957364
$1,730.73
in general payments reported to CMS, 2019-2025
21 companies · $798 in 2025
The $798 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $59.24 · 2022: $39.39 · 2023: $457 · 2024: $378 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $323.85 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $190.31 | 2023-2025 | Veozah |
| Glaxosmithkline, LLC. | $179.70 | 2022-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.29 | 2023-2025 | Jardiance, Ofev |
| Abbvie INC. | $119.55 | 2023-2025 | Vraylar, Ubrelvy |
| Ars Pharmaceuticals Operations, INC. | $81.29 | 2025 | Neffy |
| Lilly USA, LLC | $79.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $72.76 | 2019-2025 | Airsupra, Fasenra |
| Amgen INC. | $62.54 | 2024-2025 | Repatha, Otezla, Repatha |
| Abbott Laboratories | $61.22 | 2023-2025 | Freestyle Libre 3 |
| Shield Therapeutics INC | $60.36 | 2023-2025 | Accrufer |
| Sanofi-Aventis U.S. LLC | $58.69 | 2024-2025 | |
| Pfizer INC. | $58.52 | 2024-2025 | |
| Dynavax Technologies Corporation | $56.03 | 2023-2025 | Heplisav-B |
| Viiv Healthcare Company | $48.12 | 2024-2025 | Cabenuva, Apretude |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $40.03 | 2023 | Dexcom G6 Transmitter |
| Echosens North America, INC. | $19.80 | 2023 | Fibroscan |
| Otsuka America Pharmaceutical, INC. | $19.52 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $15.22 | 2019 | |
| Exact Sciences Corporation | $14.60 | 2025 | Cologuard Collection Kit |
| Pulmonx Corporation | $13.25 | 2024 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heidi Chun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.